

- 4) Bonfiglio TA, Somark TM. ASCP educational and proficiency testing programs in cytopathology. *Lab Med.* 1994;25:245-247
- 5) Davey DD, Fidler WJ. The College of American Pathologists interlaboratory comparison program in cervicovaginal cytology. *Lab Med.* 1994;25:248-252
- 6) Nielsen ML. Cytopathology laboratory improvement programs of the College of American Pathologists. Laboratory accreditation program (CAP LAP) and performance improvement program in cervicovaginal cytology (CAP PAP). *Arch Pathol Lab Med.* 1997;121:256-259
- 7) Woodhouse SL, et al. Interobserver variability in subclassification of squamous intraepithelial lesions. Results of the College of American Pathologists interlaboratory comparison program in cervicovaginal cytology. *Arch Pathol Lab Med.* 1999;123:1079-1084
- 8) Keenlyside RA, et al. Do proficiency test results correlate with the work performance of screeners who screen Papanicolaou smears? *Am J Clin Pathol.* 1999;112:769-776
- 9) Jones BA, Davey DD. Quality management in gynecologic cytology using interlaboratory comparison. *Arch Pathol Lab Med.* 2000;124:672-681
- 10) Colgan TJ, et al. Reparative changes and the false-positive/false-negative Papanicolaou test: A study from the College of American Pathologists interlaboratory comparison program in cervicovaginal cytology. *Arch Pathol Lab Med.* 2001;125:123-140
- 11) Zhai Q, Siegal GP. Quality Management in Anatomic Pathology. Northfield, IL: CAP Press, 2017.

CYP.00190 Educational Participation - Non-gynecologic Cytopathology Phase I



For laboratories that perform non-gynecologic cytopathology, the laboratory participates in an interlaboratory peer-comparison educational program in NON-GYNECOLOGIC cytopathology (eg, CAP Interlaboratory Comparison Program in Non-Gynecologic Cytopathology NGC).

Evidence of Compliance:

- ✓ Records of enrollment and participation in the educational component of the CAP NGC program **OR**
- ✓ Records of enrollment and participation in another educational non-gynecologic cytopathology peer-comparison program **OR**
- ✓ Records for participation in a laboratory-developed program by circulating non-gynecologic case material with other laboratories

QUALITY MANAGEMENT

Quality management in cytopathology should address both negative and abnormal/positive cases. The program must include both rescreening and hierarchic case review, as well as correlation of cytological and available histological material. In addition, the laboratory should participate in interlaboratory comparison, self-assessment and performance improvement programs. There must be records of intra- and extra-departmental consultation, as appropriate. Results of QM surveillance should be shared with the responsible pathologist(s) and cytotechnologist(s).

Inspector Instructions:

	<ul style="list-style-type: none"> • How are disparities between histological and cytological findings addressed? • Under what circumstances do you issue a corrected, addendum, or amended report?
---	---

CYP.01650 Cytopathology Exclusion Phase I



The institution defines specimens that may be excluded from routine submission to the cytology department for examination.

NOTE: This policy may be made in conjunction with the hospital administration and appropriate medical staff departments. The laboratory director should have participated in or been consulted by the medical staff in deciding which cytology specimens are to be sent to the laboratory for examination.